P1111: Infliximab is not Superior to Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colotis with PR3-ANCA Positive : A Retrospective Multicentre Real-World StudyECCO'25Year: 2025
Authors: Yu, Q.(1)*;Yiyu, C.(2);Chen, Y.(1);Zhu, L.(1);
(1)Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China;(2)Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Wuhan, China;
1.Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflammatory intestinal diseases. May 2021;6(2):117-122. doi:10.1159/0005153612.
2. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory bowel diseases. Feb 2007;13(2):123-8. doi:10.1002/ibd.200543.
3. Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. The American journal of gastroenterology. Aug 2010;105(8):1811-9. doi:10.1038/ajg.2010.954.
4. Liefferinckx C, Minsart C, Cremer A, et al. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. European journal of gastroenterology & hepatology. Apr 2019;31(4):478-485. doi:10.1097/meg.0000000000001356
P1112: Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: Results from three clinical trials in healthy participantsECCO'25Year: 2025
Authors: Otani, Y.(1);Feagan, B.(2,3);D’Haens, G.(4);Escobar, R.(1)*;Morris, N.(1);Payne, C.(1);Ugolini Lopes, M.(1);Zhang, X.(1);
(1)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(2)Alimentiv Inc., Medical Research and Development Department, London- Ontario, Canada;(3)Western University, Department of Medicine, London- Ontario, Canada;(4)Amsterdam University Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands;
1. Shi GH, Pisupati K, Parker JG, et al. Subcutaneous Injection Site Pain of Formulation Matrices. Pharm Res. 2021;38:779-793.
2. Williamson A and Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798-804.
3. Myles PS, Myles DB, Galagher W, et al. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth. 2017;118(3):424-429.
P1113: Efficacy and safety of Darvadstrocel (allogeneic stem cell therapy) at 6 and 12 months in refractory complex perianal fistulas in Crohn's disease. Real clinical practice in the Northwest of Spain.ECCO'25Year: 2025
Authors: De Castro Parga, M.L.(1)*;Varela, A.(2);Fernandez-Salgado, E.(3);Vigorita, V.(4);López-De los ríos, R.(5);Hernández, V.(1);Molina, G.(2);Barreiro, E.(6);Seoane, J.(7);Otero, M.(8);Gallego, J.C.(9);Romero, G.(10);Carpio, D.(11);Echarri, A.(2);Rodriguez-Prada, I.(1);
(1)Hospital Alvaro Cunqueiro CHUVI Universitary Hospital Complex of Vigo, Gastroenterology, Vigo, Spain;(2)Complexo Hospitalario Universitario de Ferrol, Gastroenterology, Ferrol, Spain;(3)estela.fernandez.salgado@sergas.es, Gastroenterology, Pontevedra, Spain;(4)Hospital Alvaro Cunqueiro CHUVI Universitary Hospital Complex of Vigo, Colorectal Surgery, Vigo, Spain;(5)Complexo Hospitalario Universitario de Ferrol, Colorectal Surgery, Ferrol, Spain;(6)Complexo Hospitalario Universitario de Pontevedra, Colorectal Surgeru, Pontevedra, Spain;(7)Complexo Hospitalario Universitario de Pontevedra, Colorectal Surgery, Pontevedra, Spain;(8)Hospital Alvaro Cunqueiro CHUVI Universitary Hospital Complex of Vigo, Radiology, Vigo, Spain;(9)Complexo Hospitalario Universitario de Ferrol, Radiology, Ferrol, Spain;(10)Complexo Hospitalario Universitario de Pontevedra, Radiology, Pontevedra, Spain;(11)Complexo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain;
Taxonera C, García-Brenes MA, Olivares D et al. Darvadstrocel for complex perianal fistulas in Crohn´s disease. A systematic review and meta-analysis. United European Gastroebnterol J 2024; Oct 3 doi 10.1012/ueg2.12673
Herreros MD, Ramirez JM, Otero-Piñeiro A et al. Use of Darvadstrocel for complex Crohn´s fistulas in real clinical practice. The national project to implement mesenchymal stem cell for the treatment of perianal Crohn´s disease (The PRIME study). Diseases colon and rectum 2024; 67(7) 960-967.
P1114: Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1AECCO'25Year: 2025
Authors: Huang, J.(1);Ran, H.(1);Zhang, X.(1);Li, S.(1);Su, C.(1);Dong, L.(1);Chen, C.(1);He, Y.(1);Liu, D.(1);Xu, X.(1);Chen, X.(1);Wang, Y.(1);Fei, K.(1);Tian, J.(1);Tian, L.(1);Peng, J.(1);Zhu, Z.(1)*;
(1)Helixon Therapeutics, Drug discovery, New York, United States;
P1115: Short- and Mid-term Effectiveness and Safety of Risankizumab in Refractory Crohn’s Disease: A Retrospective StudyECCO'25Year: 2025
Authors: Elosua Gonzalez, A.(1)*;Ramoneda , G.(1);Villalonga, L.(1);Pérez, Ó.(1);Zabalza, L.(1);Vicuña, M.(1);Nantes, Ó.(1);Rubio, S.(1);Rodriguez, C.(1);
(1)Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain;
P1116: Imaging of CCR9 in the small bowel of patients with Crohn’s disease: effects of the CCR9-depleting monoclonal antibody AZD7798ECCO'25Year: 2025
Authors: Hedin, C.R.(1,2)*;Creignou, M.(3);MacKay, J.(4);Jucaite, A.(5);Cselényi, Z.(5);Johnström, P.(5);Dahl, K.(5);Schou, M.(5);Cortés González, M.A.(6);Högnäsbacka , A.(6);Stenkrona, P.(6);Bouma, G.(4);Eck, S.(7);Lund, J.(8);Lundahl, A.(8);Kiraga, J.(9);Popińska, A.(9);Eberhardson, M.(8);Belvisi, M.G.(8);Marks, D.J.B.(4);
(1)Karolinska University Hospital, Centre for Digestive Health- Department of Gastroenterology- Dermatovenereology and Rheumatology, Stockholm, Sweden;(2)Karolinska Institutet, Department of Medicine, Stockholm, Sweden;(3)Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden;(4)AstraZeneca, Biopharmaceuticals R&D, Cambridge, United Kingdom;(5)AstraZeneca, Oncology R&D, Stockholm, Sweden;(6)Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden;(7)AstraZeneca, Biopharmaceuticals R&D, Gaithersburg, United States;(8)AstraZeneca, Biopharmaceuticals R&D, Gothenburg, Sweden;(9)AstraZeneca, Biopharmaceuticals R&D, Warsaw, Poland;
P1117: A 24-year, single-centre perianal fistulizing Crohn's disease cohort: documentation of demographics and factors influencing clinical and radiological remissionECCO'25Year: 2025
Authors: Bayar, M.(1)*;Bakkaloglu, O.K.(2);Eskazan, T.(3);Hatemi, A.I.(3);Erzin, Y.Z.(3);Celik, A.F.(3);
(1)Istanbul University-Cerrahpaşa, Internal Medicine, Istanbul, Turkey;(2)Kosuyolu High Specialization Education and Research Hospital, Gastroenterology, Istanbul, Turkey;(3)Istanbul University-Cerrahpasa- Cerrahpasa Faculty of Medicine, Gastroenterology, Istanbul, Turkey;
P1118: Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from TaiwanECCO'25Year: 2025
Authors: Meng, M.J.(1)*;Le, P.H.(1,2,3,4);Kuo, C.J.(1,2,3,4);Lai, M.W.(2,3,4,5);Chiu, C.T.(1,2,3,4);
(1)Chang Gung Memorial Hospital- Linkou Branch, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(2)Chang Gung Memorial Hospital- Linkou Branch, Inflammatory Bowel Disease Center, Taoyuan, Taiwan;(3)Chang Gung Memorial Hospital- Linkou Branch, Microbiota Therapy Center, Taoyuan, Taiwan;(4)Taiwan Association for the Study of Small Intestinal Diseases, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(5)Chang Gung Children Hospital- Linkou Branch, Department of Paediatric Gastroenterology, Taoyuan, Taiwan;
P1119: Distinct clinical features in IBD patients undergoing orthotopic liver transplantation: Associations with re-transplantation and overall survivalECCO'25Year: 2025
Authors: Wiestler, M.(1)*;Taubert, R.(1);Wedemeyer, H.(1,2,3,4);Wranke, A.(1);Lenzen, H.(1,5);
(1)Hannover Medical School MHH, Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Hannover, Germany;(2)Hannover Medical School, Cluster of Excellence RESIST EXC 2155, Hannover, Germany;(3)German Center for Infection Research, Partner Site Hannover-Braunschweig, Hannover, Germany;(4)German Liver Foundation, HepNet Study-House, Hannover, Germany;(5)Academic Teaching Hospital Braunschweig, Department of Gastroenterology- Hepatology- Interventional Endoscopy and Diabetology, Braunschweig, Germany;
P1120: ‘Early’ surgery for ileocaecal Crohn’s disease: a study of the patient perspectiveECCO'25Year: 2025
Authors: Husnoo, N.(1)*;Whitman, A.(2);Wyld, L.(1);Morgan, J.(1);Lobo, A.(3);Brown, S.(4);
(1)University of Sheffield, School of Medicine, Sheffield, United Kingdom;(2)Hull York Medical School, School of Medicine, Hull, United Kingdom;(3)Sheffield Teaching Hospitals NHS Foundation Trust, Gastroenterology, Sheffield, United Kingdom;(4)Sheffield Teaching Hospitals NHS Foundation Trust, Academic directorate of General Surgery, Sheffield, United Kingdom;
References
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785-92.
Husnoo N, Gana, T, Hague AG, Khan Z, Morgan JL, Wyld L, Brown SR. Is early bowel resection better than medical therapy for ileocolonic Crohn's disease? A systematic review and meta-analysis. Colorectal Dis. 2023; 25(6): 1090-1101.
Husnoo N, Morgan JL, Wyld L, Brown SR, P230: The challenges of implementing early surgery for terminal ileal Crohn’s disease – a qualitative study of the clinician perspective, British Journal of Surgery, Volume 111, Issue Supplement_2, March 2024, znae046.119,
P1121: Longterm Outcomes of Balloon Assisted Endoscopic Stricture Dilation in Patients with Small Bowel Crohn’s Disease: A Tertiary Referral Center's Retrospective ExperienceECCO'25Year: 2025
Authors: Halloran, B.(1)*;Bowron, J.(1);Fazal, A.(1);Kroeker, K.(1);Wong, K.(1);Hoentjen, F.(1);Parsons, D.(1);Peerani, F.(1);Gozdzik, M.(1);Wasilenko, S.(1);Zepeda-Gomez, S.(1);
(1)University of Alberta, Medicine, Edmonton, Canada;
P1122: Identification of responder subpopulations in moderately-to-severely active Crohn’s disease patients treated with mirikizumab: Results from the VIVID-1 studyECCO'25Year: 2025
Authors: Schreiber , S.W.(1);Clemow , D.B.(2);Yu , G.(2);Keefer , L.A.(3);Ananthakrishnan , A.N.(4);D'Haens , G.(5);Deepak , P.*(6);Kochhar , G.S.(7);Melmed , G.Y.(8);Chen , Y.F.(2);Moses , R.E.(2);
(1)University Hospital Schleswig-Holstein- Christian-Albrecht University of Kiel, Department of Internal Medicine, Kiel, Germany;(2)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(4)Massachusetts General Hospital and Harvard Medical School, Division of Gastroenterology, Boston, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Washington University in St. Louis School of Medicine, Division of Gastroenterology, St. Louis, United States;(7)Allegheny Health Network, Division of Gastroenterology- Hepatology- and Nutrition, Pittsburgh, United States;(8)Cedars Sinai Medical Center, Karsh Division of Gastroenterology, Los Angeles, United States;
1.M Ferrante, S Danese, M Chen, et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study, Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i7–i9, https://doi.org/10.1093/ecco-jcc/jjad212.0005.
2.Schreiber S, Hunter Gibble T, Panaccione R, et al. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024;69(7):2333-2344. doi:10.1007/s10620-024-08434-5
3.Schreiber S, Feagan BG, Louis E, et al. Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study. United European Gastroenterol J. Published online October 25, 2024. doi:10.1002/ueg2.12686
P1123: Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trialsECCO'25Year: 2025
Authors: De Greef, E.(1);Kosaras, É.(2);Béres, N.(3);Cohen, S.(4);Conklin, L.(5);Strauss, R.(5);Godwin, B.(6);Damaraju, L.(6);Zhang, R.(7);Volger, S.(6);Kim, L.(6);Van Limbergen, E.(8)*;
(1)UZ Brussels, Gastroenterology, Brussels, Belgium;(2)Central Hospital of Borsod-Abaúj-Zemplén County and University Teaching Hospital, Gastroenterology, Miskolc, Hungary;(3)Semmelweis University, Bókay Street Department- Pediatric Centre, Budapest, Hungary;(4)Morehouse School of Medicine, Gastroenterology, Atlanta, United States;(5)Janssen Research & Development- LLC, Immunology, Horsham, United States;(6)Janssen Research & Development- LLC, Immunology, Spring House, United States;(7)Janssen Research & Development- LLC, Immunology, San Diego, United States;(8)Janssen Research & Development- LLC, Immunology, Antwerpen, Belgium;
1) Mitrev N, Huang H, Hannah B, et al. Review of exclusive enteral therapy in adult Crohn’s disease. BMJ Open Gastro. 2021; 8: e000745.
2) van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2021: 171-94.
3) Becker PJ, Carney LN, Corkins MR, et al. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: indicators recommended for the identification and documentation of pediatric malnutrition (undernutrition). Nutr Clin Pract. 2015; 30(1): 147-61.
P1124: Disease Clearence after Acute Severe Ulcerative Colitis episode: is it possible ?ECCO'25Year: 2025
Authors: Markovic, S.(1,2)*;Kralj, Đ.(1);Mitrovic, M.(1);Knezevic-Ivanovski, T.(1);Kalaba, A.(1);Odanovic, O.(1);Maksimovic, B.(1);Sreckovic, S.(1);Svorcan, P.(1,2);
(1)Clinical Center University Hospital "Zvezdara", Gastroenterology and hepatology, Belgrade, Serbia;(2)Faculty of Medicine- University of Belgrade, Internal Medicine- Gastroenterology, Belgrade, Serbia;
- D'Amico F, Magro F, Siegmund B, Kobayashi T, Kotze PG, Solitano V, Caron B, Al Awadhi S, Hart A, Jairath V, Dignass A, Peyrin-Biroulet L, Danese S. Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus. Inflamm Bowel Dis. 2024 Jun 3;30(6):1009-1017. doi: 10.1093/ibd/izad159. PMID: 37549104.
2. Ramos L, Teo-Loy J, Barreiro-de Acosta M. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Front Med (Lausanne). 2023 Jan 9;9:1102420. doi: 10.3389/fmed.2022.1102420. PMID: 36698823; PMCID: PMC9868775.
3. Vuyyuru SK, Nardone OM, Jairath V. Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research. J Clin Med. 2024 Aug 1;13(15):4509. doi: 10.3390/jcm13154509. PMID: 39124775; PMCID: PMC11312513.
P1125: Robotic ileo-cecal resection in Crohn´s disease patients is feasible regardless of disease phenotype – first experience of a referral IBD centreECCO'25Year: 2025
Authors: Podmanicky, D.(1);Ferko, A.(1);Kadleckova, B.(2);Zelinkova, Z.(2)*;
(1)Nemocnica Bory - Penta Hospitals, Surgery, Bratislava, Slovakia;(2)Nemocnica Bory - Penta Hospitals, Gastroenterology, Bratislava, Slovakia;
P1126: Patterns of conventional therapy use and drivers of initiation for advanced therapy in Inflammatory Bowel Disease: A European situational analysisECCO'25Year: 2025
Authors: Agboton, C.(1)*;Halmos, T.(2);Geddes, A.(2);
(1)Takeda Pharmaceuticals, Global Medical Affairs, Cambridge, United States;(2)IQVIA, Commercial Strategy Consulting, London, United Kingdom;
1. Noor NM, Lee JC, Bond S, et al. Lancet Gastroenterol Hepatol 2024;9(5):415-427.
2. Gordon H, Minozzi S, Kopylov U, et al. J Crohns Colitis 2024;18(10):1531-1555.
3. Kumar A, Yassin N, Marley A, et al. Therap Adv Gastroenterol 2023;16:17562848231218615.
4. Michie S, van Stralen MM, West R. Implement Sci 2011;6:42.
P1127: Comparative study of Subcutaneous and Intravenous Infliximab in Inflammatory Bowel Disease: Interim analysis of a prospective single center cohort (The SWITCH study)ECCO'25Year: 2025
Authors: Liefferinckx, C.(1,2);Minsart, C.(1,2)*;Husson, C.(2);Helman, C.(1);Wambacq, V.(1);Amininejad, L.(1);Cremer, A.(1);Franchimont, D.(1,2);
(1)HUB Hopital Erasme, Department of Gastroenterology- Hepatopancreatology- and Digestive Oncology, Brussels, Belgium;(2)Université Libre de Bruxelles, Center for the study of IBD- Laboratory of Experimental Gastroenterology, Brussels, Belgium;
This interim analysis of SWITCH study demonstrates comparable drug sustainability between IFX SC and IV in a remitter IBD population. Among patients switched to SC, week 8 IFX trough levels were predictive of drug sustainability. While SC treatment showed a trend toward higher adverse events, injection site reactions were the most common and specific to the SC group.
P1128: Course of patients with Ulcerative colitis who have achieved disease clearance from the moment of diagnosisECCO'25Year: 2025
Authors: Rustamzade, A.(1)*;Hacıalioglu, C.(2);Duman, O.(2);Topuz, S.(2);Uzun, Z.(2);Telli, P.(1);Gurbanov, A.(1);Yağlı, M.A.(1);Dağcı, G.(1);Genç, S.(1);Çavuş, B.(1);Çİfcibaşı Örmeci , A.(1);Akyüz, F.(1);Demir, K.(1);Beşışık, S.F.(1);Kaymakoglu, S.(1);
(1)Istanbul University Istanbul Faculty of Medicine, Gastroenterohepatology, istanbul, Turkey;(2)Istanbul University Istanbul Faculty of Medicine, internal medicine, istanbul, Turkey;
1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090.
2. Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011 May-Jun;17(3):194-8. doi: 10.4103/1319-3767.80383. PMID: 21546723; PMCID: PMC3122090.
3. Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012 Nov;107(11):1684-92. doi: 10.1038/ajg.2012.301. Epub 2012 Nov 13. PMID: 23147523.
P1129: Comparison of discontinuation/switching between adalimumab biosimilar and originator in Inflammatory Bowel Disease patients: Preliminary data from CAN-AIMECCO'25Year: 2025
Authors: Lukusa, L.(1);Birck, M.G.(1);Moura, C.S.(1);Neville, A.(1);Zezos, P.(2);Narula, N.(3);Targownik, L.E.(4);Ma, C.(5);Purdy, E.(5);Afif, W.(6)*;Singh, H.(7);Oketola, B.(7);Bernatsky, S.(1);
(1)Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation, Montreal, Canada;(2)Thunder Bay Health Sciences Centre- Northern Ontario School of Medicine, Division of Gastroenterology- Department of Internal Medicine, Thunder Bay, Canada;(3)McMaster University, Division of Gastroenterology- Department of Medicine- Farncombe Family Digestive Health Research Institute, Hamilton, Canada;(4)Mount Sinai Hospital, Division of Gastroenterology, Toronto, Canada;(5)University of Calgary, Cumming School of Medicine, Calgary, Canada;(6)McGill University, Division of Gastroenterology, Montreal, Canada;(7)University of Manitoba, Max Rady College of Medicine, Winnipeg, Canada;
P1130: Real-life histological remission in Ulcerative Colitis patients treated with Ustekinumab: results from the Belgian SULTAN trialECCO'25Year: 2025
Authors: Holvoet, T.(1)*;Truyens, M.(2);Reenaers, C.(3);Baert, F.(4);Vandenbranden, S.(5);Anneline, C.(6);Pouillon, L.(7);Dewint, P.(8);Van Moerkercke, W.(9);Rahier, J.F.(10);Vandermeulen, L.(11);Van Dongen, J.(12);Peeters, H.(13);Lambrecht, G.(14);Vijverman, A.(15);Hoorens, A.(16);Vanhaecke, A.(16);Lobaton, T.(17);
(1)VITAZ, Gastroenterology, Sint Niklaas, Belgium;(2)Ghent University Hospital, Gastroenterology, Ghent, Belgium;(3)CHU Liege, Gastroenterology, Liege, Belgium;(4)AZ Delta, Gastroenterology, Roeselare, Belgium;(5)OLV Aalst, Gastroenterology, Aalst, Belgium;(6)Erasme, Gastroenterology, Brussels, Belgium;(7)Imelda, Gastroenterology, Bonheiden, Belgium;(8)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(9)AZ Groeninge, Gastroenterology, Kortrijk, Belgium;(10)CHU Namur, Gastroenterology, Namur, Belgium;(11)UZ Brussel, Gastroenterology, Brussel, Belgium;(12)AZ Sint Maarten, Gastroenterology, Mechelen, Belgium;(13)AZ Sint Lucas, Gastroenterology, Gent, Belgium;(14)AZ Damiaan, Gastroenterology, Oostende, Belgium;(15)CHR de la citadelle, Gastroenterology, Liege, Belgium;(16)UZ Gent, Pathology, Gent, Belgium;(17)UZ Gent, Gastroenterology, Gent, Belgium;
1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–1583.
